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Palliative care in People with Parkinson’s disease
Strategic context
Palliative care services have progressed considerably in Ireland over the 
last two decades; a notable advancement came with the publication of the 
Report of the National Advisory Committee on Palliative Care in 20011. 
Introduction
This report identified the following principles of care 
(p.31):
• “Palliative care is an important part of the 
work of most health care professionals, and all 
should have knowledge in this area, and feel 
confident in the core skills required.
• Primary health care providers in the 
community have a central role in and 
responsibility for the provision of palliative 
care, and accessing specialist palliative care 
(SPC) services when required.
• SPC should be seen as complementing and not 
replacing the care provided by other health 
care professionals in hospital and community 
settings.
• SPC services should be available to all patients 
in need wherever they are and whatever their 
disease.”
• This report also recommends that palliative 
care should be incorporated into the care plan 
of patients at an early stage of their disease 
trajectory, rather than considering palliative 
care as appropriate only in advanced disease 
or at end of life. 
Although palliative care services have been largely 
associated with cancer care, it is increasingly recognised, 
as above, that the principles of palliative care are not 
just confined to malignancy, but need to be embedded 
in frameworks of all life-limiting disease2. More recently, 
the Palliative Care Competencies Framework was 
published which outlines core competences and 
discipline specific competences for 12 health and social 
care disciplines, which apply to all life-limiting illnesses3. 
The role of palliative care specifically in neurological 
disease in Ireland has been highlighted4. A series of Irish 
research studies have indicated a need for healthcare 
workers (HCW) to have better training and skills in 
palliative care for people with Parkinson’s disease5, 6. 
The aim of these guidelines is to provide practical 
guidance on the assessment and management of 
palliative care needs in Parkinson’s disease and 
Parkinsonian syndromes (PD; see Appendix I for list of 
abbreviations).
Development of the guidelines
The Irish Hospice foundation funded the development of 
these guidelines following a successful grant application. 
A steering group was established, and a part-time 
research co-ordinator was appointed in October 2013. 
Three independent primary research studies were 
conducted with HCW; people with PD; and families/
carers; to explore palliative care needs in advanced PD. 
These studies have highlighted a need for HCW to have 
better training and skills in palliative care for people with 
PD5-7. 
In the summer of 2014, an expert advisory group for the 
guidelines was established, and the first meeting of the 
group was held in October 2014 (see Appendix II for 
a list of members of the steering group and advisory 
committee).The Guideline Developers Manual of the 
National Clinical Effectiveness Committee8 informed the 
development process for these guidelines. The goal was 
not to create new guidelines, but to adapt existing high 
quality guidelines to the Irish context. A comprehensive 
search was performed to identify previously published 
guidelines for palliative care in PD. No guidelines were 
found which exactly met this criteria, however a number 
of documents which are relevant to the aims and 
objectives of this guideline were located. 
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The primary documents which were adapted for the 
current guidelines are:
• NHS England [formerly the National End 
of life Care Programme] (2010). End of life 
care in long term neurological conditions: A 
framework for implementation. The National 
Council for Palliative Care; the Neurological 
Alliance; NHS National End of life Care 
Programme.9
• The National Council for Palliative Care (2012). 
Parkinson’s and the last days of life: Consensus 
statement on the management of symptoms 
for people with Parkinson’s and related 
conditions in the last few days of life.10 
A second comprehensive search was conducted to 
identify guidelines for symptom management in PD. 
The guidelines included were published by the following 
groups:
• National Institute for Health and Clinical 
Excellence (NICE; 2006)11
• Scottish Intercollegiate Guidelines Network 
(SIGN; 2010)12
• Movement Disorder Society 
 (MDS; 2011, 2011)13, 14
• American Academy of Neurology (AAN; 
2010)15
• European Federation of Neurological Societies 
(EFNS, 2011)16 
Where recommendations are taken from one of 
these existing guidelines, the source for the original 
recommendations (NICE, SIGN, MDS, AAN or EFNS) is 
referenced. The systems for determining the level of 
evidence that were used across the guidelines differed 
slightly but the grade for the recommendation was 
maintained from the original source (see Appendix 
III for detailed grade system for each guideline). A 
systematic review of the peer-reviewed literature was 
also conducted to identify relevant studies which were 
published since the publication of these guidelines (this 
was conducted in March 2015 and reviewed literature 
published between 2010 and 2015). Studies were 
included where they were of high quality and were not 
referenced in previous guidelines. The search strategy is 
detailed in Appendix IV.
A draft guidelines document was developed following 
the above rigorous processes, overseen by the advisory 
group. The draft document was sent for international 
expert review in July 2015 (reviewed by Professor David 
Oliver and Professor Anette Schrag). Minor changes 
were made following their feedback, and accepted 
by the advisory group. Finally, the guidelines were 
distributed for public consultation in Ireland between 
August and September 2016. A list of the individuals /
organisations who provided feedback during the public 
consultation process is provided in Appendix V. Again, 
changes were approved by the advisory group. Final 
editing and proof-reading was undertaken in April 2016.
The current guideline was needed as there existed no 
previous comprehensive overview of palliative care 
needs in PD. While the existing NHS England9 document 
covered end of life care in neurological illnesses, the 
current guideline expands on this development by 
adding information specifically related to the care of 
people with PD. Furthermore the current guideline adds 
information on the drug and non-drug management of 
symptoms relevant to the end of life period, based on 
recent research.
Background
Parkinson’s disease is a progressive neurodegenerative 
condition, resulting from the death of the dopamine 
producing neurons in the substantia nigra of the mid 
brain, and is currently incurable. Thus all treatment is 
symptomatic, with an average life expectancy post 
diagnosis of 15 years, although this can vary greatly. For 
example, being diagnosed with Parkinson’s disease at an 
older age is associated with decreased life expectancy17. 
Parkinsonian syndromes, such as progressive 
supranuclear palsy (PSP) and multiple system atrophy 
(MSA) have shorter life expectancies, about eight years 
after symptom onset or within four years of diagnosis18.
Parkinson’s disease is the second most prevalent 
neurological disease in Europe, after Alzheimer’s 
disease. It affects 1% of those over 60 years, and 2% 
over 80 years of age (approximately 12,000 people in 
Ireland19). Because the risk of developing Parkinson’s 
disease increases with age, the fact that more people are 
now living into old age means that the overall number 
of people with Parkinson’s disease is also rising. The 
prevalence of Parkinson’s disease is expected to more 
than double by 203020.
Burden of PD
PD is a substantial burden on the person, and also 
their families and carers11, 21. Considerable research 
has documented caregiver burden in Parkinson’s 
disease, including depression, stress, strain, fatigue and 
mortality22, 23.
Economic impact 
The economic consequences of Parkinson’s disease 
include both direct and indirect costs. Direct costs 
include the cost of medicines and medical care and aids/
equipment and adaptations. Indirect costs include early 
retirement or loss of employment for the person with 
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Parkinson’s disease, reduced working hours for carers, 
and the costs of additional home or institutionalised 
care24.
One study found that the average semi-annual (6 
month) cost per patient with Parkinson’s disease across 
four Western European countries was €7442.5025. As 
the population continues to age, the economic burden 
related to Parkinson’s disease will continue to escalate.
A more recently published study in the United States26, 
found that the annual utilization of health services and 
cost for the Parkinson’s disease cohort was significantly 
higher than for a control population. On an annual basis, 
a person with  Parkinson’s disease spent approximately 
two more days in hospital, 43 more days in long-
term care institutions, and fill more than 20 more 
prescriptions than do the controls. The total annual cost 
is more than double that of the control population, even 
before adding indirect costs (uncompensated care, 
productivity loss, etc.).
Guideline title: Palliative care in People with Parkinson’s 
disease: Guidelines for professional healthcare workers 
(HCW) on the assessment and management of 
palliative care needs in Parkinson’s disease and related 
Parkinsonian syndromes.
What the guideline covers: Complex symptom 
management of Parkinson’s disease and related 
Parkinsonian syndromes, especially in advanced disease.
What the guideline does not cover: Symptom 
management in Parkinsonism (e.g.  isolated shuffling 
gait, medication induced tremor, age related slowness of 
movement); diagnosis and early assessment;  treatment 
of early Parkinson’s disease and related Parkinsonian 
syndromes.
Scope: This guideline is not intended as a policy 
document. This guideline will form part of any future 
full Irish guidelines for PD. This guideline will serve as 
an information document for HCW who may be unsure 
of the appropriateness of a palliative care approach, or 
referral to SPC. Readers are also directed to the referral 
criteria for SPC developed by the National Clinical 




Population: People with idiopathic Parkinson’s disease 
and related Parkinsonian syndromes (PD), their 
carers, and family members. Parkinsonian syndromes 
include: Multiple System Atrophy (MSA), Progressive 
Supranuclear Palsy (PSP), Corticobasal Degeneration 
(CBD), Lewy Body Dementia (LBD), and Parkinson’s 
Disease Dementia (PDD).
For convenience, Parkinson’s disease and related 
Parkinsonian syndromes will be referred to as ‘PD’ 
throughout this document, unless otherwise indicated. 
Where certain management and treatment may be 
different for a particular Parkinsonian syndrome, this will 
be highlighted in the guidelines
Users: These guidelines are intended for all professional 
healthcare workers who are involved in the care of 
people with PD and their carers/families, in any acute, 
community, or residential setting in Ireland. 
Aim and objectives of the guideline
Aim: To provide practical guidance on the assessment 
and management of palliative care needs in Parkinson’s 
disease.
Objectives:
1 To optimise function and quality of life in 
people with PD
2 To highlight the benefits of a palliative care 
approach for people with PD
3 To provide information to HCW who may be 
unsure of the appropriateness of adopting  a 
palliative care approach in PD
4 To promote access of people with PD  to SPC 
services, when required
5 To raise awareness of the prevalence of 
cognitive impairment / dementia in late PD 
6 To promote timely care planning and 
intervention
7 To improve the cohesiveness of the approach 
of the health / social services provided to 
people with PD, and hence improve the quality 
of care of the person with PD.
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It is important to note that this definition does not refer 
to any one disease, and the definition can be applied to 
any “life-threatening illness”. As PD is currently incurable, 
it is important that a “palliative care approach” is used 
from the outset – i.e. a focus on assessing and managing 
symptoms and improving quality of life throughout the 
course of this life-limiting illness, complementing but not 
replacing other treatments. This does not necessarily 
mean that the person with PD needs to be referred to 
a SPC team or a hospice, just that all HCW are aware 
that promotion of quality of life is the main goal of care. 
Table 1 outlines three levels of palliative care provision. 
However, there may come a time in the disease that SPC 
team input would be valuable. The trigger for this is that 
the patient has unmet care needs that can’t be met by 
other services. This doesn’t depend on disease duration 
or stage – please refer further to the National Clinical 
Programme for Palliative Care guidance on palliative 
care needs assessment: http://www.hse.ie/eng/about/
Who/clinical/natclinprog/palliativecareprogramme/
Resources/needs%20assessment%20guidance.html 28). 
It is useful to note that the advanced disease phase in 
PD may last about 2.2 years29, although in PSP, CBD and 
MSA there can be a more sudden and rapid decline. This 
advanced phase in Parkinson’s disease may be defined30 
by:
• The presence of advanced comorbidity
• Inability to tolerate adequate dopaminergic 
therapy
• Unsuitability for surgery
This advanced stage should trigger very frequent re-
assessments for unmet palliative care needs. 
All HCW working with people with PD should be familiar 
with the Palliative Care Competence Framework, 
especially as it applies to their specific discipline. The 
framework describes core competences and discipline 
specific competences for twelve health and social care 
disciplines, and is designed to foster inter-professional 
and inter-organisational collaboration in palliative care 




Dynamic involvement of palliative care throughout the 
illness
The progression of PD is highly variable, making 
planning challenging. It is therefore essential that 
each person is assessed regularly and their changing 
needs are managed on an individual basis. There are 
tools available for assessing palliative care needs in 
Parkinson’s disease, but not all are validated in this 
Palliative Care 
Approach in PD
The World Health Organisation27 defines palliative care as: 
“An approach that improves the quality of life of individuals and their 
families facing the problem associated with life-threatening illness, through 
the prevention and relief of suffering by means of early identification 
and impeccable assessment and treatment of pain and other problems, 
physical, psychosocial and spiritual.”
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population. Tools include the Edmonton Symptom 
Assessment Scale PD (ESAS-PD31), Palliative Care 
Outcome Scale for Symptoms (POS-PP32), Functional 
Assessment of Chronic Illness Therapy Spiritual 
Wellbeing (FACIT-Sp33), Zarit Caregiver Burden Index 
(ZCBI34), and and Needs Assessment Tool-Parkinson’s 
Disease (NAT-PD35).
As individual needs vary over time, a model of dynamic 
involvement of palliative care services should be 
adopted (see ‘model C’ in figure 1). A general palliative 
approach is applicable from diagnosis. General and 
specialist palliative care might become more involved 
at times of particular symptoms or psychosocial issues, 
e.g. pneumonia, marked functional decline, spiritual 
crisis, as well as at the very end of life9. It is important to 
note that people with PD may have periods where they 
require SPC input, but can emerge from these to a state 
at or close to their level of function and quality of life 
before the episode. This highlights the appropriateness 
of ‘model C’ and emphasises that palliative care is not 
synonymous with end of life. 
Another key feature is that SPC input has to be 
integrated with usual care, with the SPC team working 
alongside the usual treating HCW. Critical to this 
dynamic model of care is good coordination and 
communication between all professionals involved in the 
MDT, to maximise quality of life for the person with PD 
and their family.
PD and related disorders
The term “Parkinsonian syndromes” refers to a group 
of diseases that are all linked to an insufficiency of 
dopamine in the basal ganglia - the part of the brain 
that controls movement. Symptoms include tremor, 
bradykinesia (extreme slowness of movement), flexed 
posture, postural instability, and rigidity, but the 
extent and severity can vary within the syndromes. 
Idiopathic Parkinson’s disease is responsible for 85% of 
all Parkinsonian syndromes36. Parkinsonian syndromes 
exhibit the main symptoms of PD, mentioned above. 
Additional features that are characteristic of the other 
diseases are as follows37:
Multiple System Atrophy (MSA): MSA is characterized 
by symptoms of autonomic nervous system failure 
(symptomatic postural orthostatic hypotension, bladder 
and bowel dysfunction, erectile dysfunction in men, and 
urinary retention). Other features include increasingly 
Level 1 – Palliative Care Approach Palliative care principles should be practiced by 
all health care professionals. The palliative care 
approach should be a core skill of every clinician at 
hospital and community level. Many individuals with 
progressive and advanced disease will have their 
care needs met comprehensively and satisfactorily 
without referral to specialist palliative care units or 
personnel.
Level 2 – General Palliative Care At an intermediate level, a proportion of individuals 
and families will benefit from the expertise of health 
care professionals who, although not engaged full 
time in palliative care, have had some additional 
training and experience in palliative care, perhaps 
to diploma level. Such intermediate level expertise 
may be available in hospital or community settings. 
Level 3 – Specialist Palliative Care SPC services are those services whose core activity 
is limited to the provision of palliative care. These 
services are involved in the care of individuals with 
more complex and demanding care needs, and 
consequently, require a greater degree of training, 
staff and other resources. SPC services are available 
within primary care settings, acute general hospital 
settings and specialist inpatient units.
Table 1. Levels of palliative care specialisation (NACPC1: 32)
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impaired speech and muscle co-ordination, poor 
balance, and rigidity.
Progressive Supranuclear Palsy (PSP): The cardinal 
symptoms of PSP include frequent falls, prominent 
bulbar symptoms especially dysphagia, vertical gaze 
palsy, and emotional and personality changes.
Corticobasal Degeneration (CBD): The main symptoms 
of CBD are apraxia (an inability to perform coordinated 
movements or use familiar objects), pronounced 
asymmetry often associated with hemiplegia, stiffness 
that is more severe than classic PD, including marked 
dystonia, and myoclonus (twitching or jerking) usually in 
the hand.
Lewy body dementia (LBD): The central feature of 
LBD is progressive cognitive decline, combined with 
pronounced fluctuations in alertness and attention, 
complex visual hallucinations and motor symptoms, such 
as rigidity and the loss of spontaneous movement.
Parkinsonian syndromes including MSA and PSP may 
be difficult to distinguish initially from PD, but most 
are usually less responsive to medication and the 
progression of symptoms is generally more rapid. 
The prognosis is usually two to four years from 
diagnosis – people develop considerable disability and 
require careful assessment and care. This requires a 
modified palliative care plan, earlier and more intense 
involvement, and regular review.
Figure 1. (Reproduced with permission from: NHS England9, page 11)
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Opening dialogue about prognosis and care planning 
for the future is important and evidence suggests that 
advanced planning enhances the quality of care38. 
However, some people with PD or their family will not 
want to engage with palliative care or care planning, 
at least at first introduction. Equally, HCW need to be 
sensitive to indicators that a person or family want or 
need to have such a discussion, and HCW need to be 
able to facilitate this. However many HCW are reluctant 
to engage in advance care planning and end of life care 
discussions with people: fear of causing distress, role 
uncertainty, appropriate time and lack of confidence39. It 
is important that these challenges are overcome so that 
the person with PD and their families40 are:
• given timely information
• can make informed decisions about their 
future care
• have realistic expectations
• avoid inappropriate burdensome interventions 
at the end of life 
In planning the care of a person with PD, it is obviously 
important to know the core values of the person. As 
the majority of people with advanced PD may have 
communication difficulties and cognitive impairment, 
these discussions may need to occur earlier in the 
disease than might occur in other conditions, as the 
person may not be able to contribute to the discussion 
in later stages of the disease. 
An important point about discussions, conversations and 
dialogue with the person with PD, is that these need to 
be documented and communicated to the relevant MDT 
members, to avoid multiple questionings about the same 
issue. However, this is a dialogue over time, and the 
person’s views and wishes may change, so revisiting an 
issue is sometimes very appropriate.
Communication throughout the illness
Discussing disease progression and prognosis 
(particularly in Parkinsonian syndromes with poor 
prognosis) can be difficult. Individual styles of 
conversation may vary between people, and clinicians 
need to be sensitive to this. Thus the following are 
intended as a guide to conversations, remembering that 
each person with PD is different (adapted from NHS 
England9):
In general
• Start difficult discussions at or soon after 
diagnosis by exploring peoples’ attitudes and 
views before decisions have to be made and 
any possible cognitive change has developed
• Recognise that this is a process rather than a 
single event and will need to be revisited in 
future consultations
• Ensure that the person / carer understand 
the reason for referral to palliative care – this 
might involve a description of the possible 
role of SPC for their particular symptom at 
that time. It is important that the person 
understands that this is not a handing over of 




Effective communication and patient education early in their illness 
is essential to empower people with PD and their carers to feel they 
can be an equal partner with HCW in their illness. Equally, effective 
communication between HCW facilitates consistent and coordinated 
care. All members of the MDT should therefore develop a therapeutic 





• Invite the person to bring someone with them 
for a planned meeting
• Ensure a private room is available, free from 
distractions and interruptions, and that the 
person can remain there after the discussion, 
to rest and reflect if necessary
During: Conveying important information
• Convey the information sensitively and at a 
pace that is manageable for the person; avoid 
medical jargon
• Allow time for crucial information to sink in; 
some may need to hear the same information 
several times
During: Listening
• Elicit the person’s perceptions of their illness
• Keep checking that the person understands 
what has been said. For example, ask open 
questions to gauge their level of understanding
• Allow the person to express their feelings, and 
have these acknowledged 
Follow-up
• Offer literature about their condition to read 
later, and provide information about sources 
of support, e.g. PD groups and patient 
organisations
• Provide a follow-up contact number and 
arrange a review appointment in the near 
future for further discussion
• Document the conversation and ensure 
relevant MDT members are informed
Supporting the individual and their family and ensuring 
appropriate communication is important in facilitating 
the individual to come to terms with the reality of having 
an incurable and progressive neurological disease. 
Helping individuals and their families understand what is 
happening now, and how they can best deal with what 
may happen in the future, is the cornerstone of good 
neurological care, and is particularly important in PSP, 
CBD, and MSA where prognosis is poorer. In patients 
with a Parkinsonian syndrome that involves prominent 
cognitive impairment, and perhaps poor insight into their 
own condition, it is important to speak with carers as 
well as the patient when enquiring about symptoms and 
when discussing important information.   
Discussing potentially life-prolonging treatments
Many potentially life-prolonging treatments are used in 
advanced PD without knowledge of the person’s wishes. 
These include treatment of serious infections with 
antibiotics, and intravenous / subcutaneous hydration, 
and less commonly enteral nutrition, artificial ventilation, 
and cardiopulmonary resuscitation9.
People’s preferences should always be considered. 
These may differ from the preferences of the family / 
carer. This needs to be acknowledged and managed 
skilfully. It is particularly important that a person’s 
family do not feel overly burdened by feeling they are 
“responsible” for making decisions about medical care. 
“It requires great sensitivity to discuss these delicate 
matters and to discern who does and who does not 
wish to receive life-prolonging treatment. These difficult 
discussions are at the heart of compassionate care, 
respecting the person’s autonomy and helping them to 
make choices in keeping with their own circumstances, 
attitudes and beliefs. These discussions should start at 
diagnosis. This is the opportunity to find out about the 
person’s attitudes, before decisions have to be made 
and cognitive changes have developed. Regular review 
of care needs is essential.”9. All HCW involved in the care 
of a person with PD should be comfortable in discussing 
care decisions, including life prolonging treatments, 
within their own competencies. Informal or impromptu 
discussions can be followed by a formal meeting with 
more members of the MDT, as appropriate, including 
the person with PD wherever possible, and relevant 
carers / family members, so that the person’s / carer’s 
questions can be fully answered, family members get to 
hear the same information, and a plan for future care can 
be discussed based on up-to-date information on the 
person’s current status. 
Suggested prompts for talking about life-prolonging 
treatments9:
 “Has it been helpful in the past to know a bit 
more about your condition?”
 “Do you like to know what is happening with 
your condition?”
 “Would it be helpful to talk about how this 
condition may progress from here?”
 “How have you been coping with things since 
you found it harder to swallow?”
 “What you would like to see happen from 
here?”
9
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Discussing advance care planning
Advance care planning is “a term to describe an advance 
expression of wishes by a person at a time when they 
have the capacity to express their wishes, about certain 
treatment that might arise at a future time when they no 
longer have capacity to express their wishes”41.  Advance 
care plans can improve end of life care, improve family 
satisfaction, reduce stress, anxiety and depression in 
surviving relatives38. Advance care directives will be 
discussed separately later.
The need for information and the wish to write an 
advance care plan will vary between individual cases. 
However clinicians should provide the opportunities to 
have open and honest conversations – including end 
of life care discussions – at all stages of the illness9. 
There may be times when clinicians need to actively 
encourage advance care planning, e.g. when discussing 
life prolonging treatments, as above. The difficulties 
in diagnosing PSP, CBD, and MSA often mean that 
people can have quite advanced illness and significant 
communication difficulties at diagnosis and advance 
care planning may be appropriate soon after diagnosis. It 
is important to open the dialogue with the person about 
their disease, including an opportunity for advance care 
planning if the person wants this, early in these disease 
trajectories, soon after diagnosis. 
Specific issues around care planning in advanced disease 
/ end of life care are discussed later under the heading 
“Planning Future Care and End of life Care in PD”.
It is also important that the MDT is kept updated of 
relevant changes in the person’s condition or wishes, 
particularly the GP, who is often the first point of call 
of the person / carers. A well-functioning MDT will help 
to ensure that all aspects of the person with PD and 
their families’ needs are met, in any setting. Excellent 
communication between professionals is essential to 
avoid problems such as: individuals receiving conflicting 
information; individuals and their carers having to repeat 
information many times; having anxiety and confusion 
over who to contact if a particular problem arises; and 
poor communication resulting in inappropriate hospital 
admissions. See Appendix VI for a list of HCW who may 
be involved in the MDT.
Model of best practice
Two integrated palliative care and Parkinson’s disease 
services, in Scarborough UK and in Alberta Canada, 
serve as models of best practice in care. Based on their 
experiences, it is important for neurology / geriatrics, 
rehabilitation, and palliative care teams to develop 
closely co-ordinated working links to support all people 
with PD from diagnosis to death, including:
• Proper flow of communication and information 
for people and their families
• A designated point of contact for each stage 
in the pathway
• A needs assessment identifying the patient’s 
individual problems
Co-ordinated care in Ireland could be greatly enhanced 
by electronic care records. In order to achieve the best 
quality of care, professionals must be able to recognise 
when their own experience is limited, and when to 
contact other specialists for support.
Multidisciplinary 
Care
It is important that there is a clear, defined pathway to follow when an 
individual needs help or advice. Team members may be geographically 
dispersed so it is good practice to have a single point of contact, i.e. a ‘key 
worker(s)’. It is essential that the individual, their carers, and the primary 
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This section will be divided into sections that correspond 
with the four focus areas of palliative care:
• Physical: e.g. pain, breathlessness, rigidity
• Psychological: e.g. depression, anxiety, 
cognitive impairment
• Social: e.g. loss of employment, role change
• Spiritual: e.g. religious and non-religious 
issues,  asking ‘why me’?
In reality, these four domains have complex, interlinked 
relationships (e.g. factors and changes in the social, 
psychological or spiritual domain may influence the 
experience of physical symptoms by the person), 
and they are separated out in this guideline only for 
structure. 
In some subsections of Physical and Psychological Care, 
symptom assessment and management will be discussed 
separately for i) advanced disease and ii) end of life care. 
This occurs where the symptom commonly also occurs 
at end of life, and / or the assessment / management 
may be different at end of life. Recognising advanced 
disease and recognising end of life will be specifically 
discussed in a later section.   
Managing 
Distress in PD
This section discusses the management of advanced PD, typically the 
final one to two years of life. Where “end of life” care is referred to, this 
is intended to mean “care that is provided during the period when death 
is imminent, and life expectancy is limited to a short number of hours or 




The causes of rigidity in advanced PD include disease 
progression, variability in response to dopaminergic 
medication and increased intolerance to these 
medications due to neuropsychiatric symptoms, and 
in those dying of their PD, decreasing drug efficacy. 
The balance between relieving rigidity without causing 
agitation, hallucinations, or somnolence can be difficult, 
thus expert Parkinson’s advice may be required. 
Decisions around patient appropriateness for complex 
PD therapies such as the continuous infusions therapies 
subcutaneous apomorphine and jejunal levodopa /
carbidopa, and Deep Brain Stimulation (DBS) surgery, 
will usually have been made prior to this advanced stage 
of illness.
Potential options include (adapted from NCPC10 unless 
otherwise indicated):
• Make sure the person gets their dopaminergic 
medication on time (if swallow is intact).
• Consider addition of PRN doses of dispersible 
levodopa / benserazide formulations (i.e. 
Madopar dispersible) 
• If dysphagia is interfering with medication 
administration, regular levodopa / carbidopa 
formulation (Sinemet) tablets can be crushed 
or dissolved in water. Note: crushing or 
dissolving medications will speed up onset of 
action but also shorten duration of action, so 
more frequent / lower doses may be needed
• Consider giving dopaminergic drugs via 
Percutaneous Endoscopic Gastrostomy (PEG) 
or via Nasogastric (NG) tube; NG use may be 
especially appropriate for medication delivery 
during periods of acute intercurrent illness 
where there is an expectation of recovery. 
• Regular levodopa / carbidopa formulation 
(Sinemet) tablets can be crushed, but 
extended release dopamine agonists, or 
levodopa, combination medications such 
as levodopa / entacapone / carbidopa 
(Stalevo) can’t be crushed, and so patients 
should be converted to the equivalent dose 
of regular levodopa / carbidopa. A PD expert 
or pharmacist can give advice about drug 
equivalencies and suitability of a particular 
formulation for crushing / dissolving.
• Consider rotigotine transdermal patches if 
enteral administration of medication is not 
possible (start low and titrate slowly; seek 
advice from a PD expert as soon as possible as 
rotigotine may worsen confusion or agitation 
in advanced PD). Optimal nursing care and 
pressure area management is vital in all cases.
End of life rigidity care: In the final hours / days of life, 
if it is impossible to administer dopaminergic medication 
(oral medications impossible and transdermal / 
subcutaneous dopamine agonist therapy contra-
indicated or inappropriate, e.g. delirium, hallucinations), 
then midazolam in a subcutaneous infusion may be 
efficacious, although specific research to support this 
is currently lacking. Clinical judgement, with expert 
advice if needed, should be used to determine dose, as 
midazolam is a potentially potent sedative.
Pain
It is important not to assume that the pain is related 
to the PD, therefore optimal assessment and regular 
review are vital, to determine the precise mechanism 
of the pain, and hence guide treatment. It is important 
to identify reversible causes of pain (e.g. retention). 
Receiving usual dopaminergic medication on time, if 
swallowing, is also important.
The priority is to formally and regularly assess pain / 
comfort; the best means of doing this will depend on the 
person, situation and staff member. In routine clinical 
Physical Care
Management of physical symptoms is an essential element of the holistic 
care of the individual and their carer / family. Physical symptoms requiring 
palliative care may include the following:
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practice, a clinical assessment of pain by a competent 
HCW may suffice. Visual pain scales may be used 
for patients with communication difficulties. It is also 
important to consider non-verbal indices of pain, such 
as groaning, agitation, tearfulness. Consideration may 
be given to specific pain assessment tools such as the 
King’s PD pain scale43 (currently in development), or in 
patients with PD dementia, dementia pain scales such 
as the Abbey pain scale44, Pain Assessment Checklist 
for Seniors with Limited Ability to Communicate45 
(PACSLAC), or DOLOPLUS246, bearing in mind that 
they have been developed and validated in a different 
population. 
If the pain is due to rigidity, see previous section. If not 
consider both non-pharmacological and pharmacological 
interventions9.
Non-pharmacological interventions: In advanced 
PD, non-drug interventions are also important in 
controlling pain. These interventions include: nursing 
care; occupational therapy; physiotherapy; positional 
/ postural changes; pressure-relieving devices; 
Transcutaneous Electrical Nerve Stimulation (TENS); 
heat; massage and acupuncture. Physiotherapist 
prescribed passive range of motion exercises provided 
by the family may also provide relief by maintaining 
range and function. However it should be noted that 
this evidence is limited and extrapolated from other 
neurological conditions47.
Pharmacological interventions: The World Health 
Organistaion48 analgesic ladder was developed for 
cancer related pain. It is often used as a framework for 
prescribing analgesic pain relief. This involves initially 
using simple analgesics, such as paracetamol (Step I), 
progressing to weak opioids (e.g. codeine, tramadol) for 
mild to moderate pain (Step II), and then strong opioids 
(e.g. morphine, oxycodone) for moderate to severe pain 
(Step III), with other adjuvant analgesics, when required. 
However, it is increasingly recognised that a low dose 
of a strong opioid may be preferable to a high dose of 
a weak opioid in terms of analgesic effect / side effect 
balance. The EAPC recommendations for opioid use 
in cancer pain49 include low doses of strong opioids in 
Step II, with higher doses of these drugs in Step III. For a 
person with swallowing difficulties, opioids can be given 
as oral solutions or subcutaneously / transdermally. For 
acute pain, parenteral routes will give better analgesic 
effect than transdermal administration. Difficult to 
manage pain is an indication to seek SPC input. Most 
analgesia increases risk of constipation, a common 
symptom in all PD conditions. Monitoring bowel 
function and titrating laxatives is important to facilitate 
optimal absorption of PD medications. Please refer to 
the NCEC guidelines “Management of Constipation 
in Adult Patients Receiving Palliative Care” for more 
information50.
Other medication may be needed in PD-related pain, e.g. 
anti-spasticity drugs. Neuropathic pain is common in PD, 
and should always be considered. Where a person can 
describe their pain, important clues to neuropathic pain 
are sensory symptoms such as numbness or paresthesia, 
and the quality of the pain (burning or radiating / 
“travelling”). A detailed neurological examination may 
elicit abnormal motor, sensory, or autonomic nerve 
function, suggesting that pain may be neuropathic. 
Validated tools to differentiate neuropathic pain from 
other types of pain include subjective tools such as 
Neuropathic Pain Questionnaire (NPQ)51, ID Pain52, and 
PainDETECT53; and tools that include examination, such 
as the Leeds Assessment of Neuropathic Symptoms 
and Signs scale (LANSS54) and Douleur Neuropathique 
en 4 Questions (DN4)55, which are more sensitive56. 
None of these have been developed or validated in a PD 
population. The treatment of neuropathic pain includes 
anti-convulsant agents (gabapentin and pregabalin) and 
anti-depressants (amitryptiline, duloxetine).
End of life pain care:  If pain has not been a problem 
earlier in the illness it is unlikely to be so as death 
approaches. A dying person may not be able to report 
pain directly but if they appear restless or uncomfortable 
and a reversible cause such as a full bladder or 
bowel has been ruled out it is appropriate to try an 
analgesic9. Please refer also to the NCEC guideline on 




Breathlessness in advanced disease is primarily caused 
by respiratory muscle weakness. Positional changes and 
postural supports, and chest physiotherapy and cough 
augmentation to mobilise secretions, can be helpful. 
People with PD may also have restrictive lung deficits, 
due to rigidity / dystonia either in “off periods” or as a 
result of reduced responsiveness to levodopa.  Extreme 
trunk flexion, forwards or laterally, can compromise 
lung expansion, exacerbated by vertebral osteoporotic 
fractures; while muscle wasting in advanced disease 
can affect diaphragm / intercostal muscle strength. 
Aspiration can further worsen dyspnoea. Incentive 
spirometry is said to be helpful for restrictive deficits, 
but motivation and caregiver fatigue can make this 
difficult. It is important to look for reversible causes of 
dyspnoea (super-imposed heart failure, pneumonia). 
Opioids and / or benzodiazepines are useful for easing 
the distress of breathlessness9. Support to manage the 
anxiety related to breathlessness is an important part 
of the treatment of dyspnoea (e.g. patient education on 




End of life dyspnoea care:  At the end of life, a person 
with PD may have a reduced ability to cough, and can 
accumulate secretions in the upper airways. This can 
result in noisy breathing which is distressing for families 
/ carers. Firstly it is important to explain to the family 
why the breathing is noisy, what is being done and what 
its limitations are. Of note, there are no specific studies 
in PD, but a Cochrane review of treatments (revised 
201259) in adult and children populations found no 
evidence of benefit of any agent to control established 
secretions at end of life. However, the guidelines group 
noted that a lack of evidence of benefit to date does 
not definitively out rule an actual benefit, and these 
agents are widely used in clinical practice. Of note, 
recent NICE guidelines for the care of dying adults in the 
last days of life60 recommend a trial of these agents if 
noisy respiratory secretions are present. The guidelines 
group suggests early introduction of these agents, with 
prophylactic intent, at end of life, rather than waiting 
to begin treatment in established secretions, when 
effects may be less (GPP). Suitable agents include 
hyoscine hydrobromide or butylbromide, atropine, 
and glycopyrrolate, with no clear advantage to any 
one agent as first line treatment. Patient positioning, 
suctioning (if appropriate), and avoiding overhydration 
also form part of the overall management. 
Dyspnoea can be treated with opioids and / or 
benzodiazepines. It is important to note that at end of 
life, these agents do not have any negative impact on 
respiratory function. 
Communication difficulty
As PD progresses, and particularly in MSA, PSP and 
CBD, the person’s ability to speak and be understood 
can reduce. This can be a combination of low volume 
voice and dysarthria. Speech and language therapy can 
improve communication quality (particularly through 
voice treatment programmes such as the Lee Silverman 
Voice Technique [LSVT]), and where necessary explore 
voice and communication assistive technologies. All 
people with PD should have an effective method for 
communication throughout their disease11.
Dysphagia and sialorrhea
Patients should be referred early to speech and 
language therapy for assessment and management as 
dysphagia can occur in up to 80% of people with the 
condition61 (GPP).  Silent aspiration is also an increasing 
risk in advanced PD62. Further instrumental investigation 
such as videofluorscopy may be considered appropriate 
by the speech and language therapist.
There is insufficient evidence to evaluate swallow 
rehabilitation in PD16 though a recent systematic review 
suggests that Expiratory Muscle Strength Training 
(EMST) and Video-Assisted Swallowing Therapy (VAST) 
may be treatment options for dysphagia in PD63. The 
management of severe dysphagia usually involves 
regular clinical evaluation of the swallow function and 
consideration of:
• modifying food and liquid consistency
• modifying medication timing and formulation 
(see earlier section on rigidity/stiffness)
• introducing swallowing manoeuvres 
• co-ordinating meal times with “on” times
• educating and training caregivers (GPP)
Treatment of dysphagia is always multidisciplinary in 
nature and patient-focussed. The maintenance of good 
oral hygiene is also important for comfort. 
Glycopyrrolate can be useful for the short term 
treatment of sialorrhea in PD (MDS14, Grade A). There is 
insufficient data on the efficacy of other anti-muscarinic 
agents, and they may worsen confusion in advanced PD 
(this includes hyoscine patches). Botulinum injection 
of salivary glands, if available, has proven efficacy for 
sialorrhoea in general populations, and specifically 
in PD (Grade B), and due to its local effects, can be 
used in advanced disease without causing cognitive 
deterioration. Atropine drops can be used sublingually 
in selected cases where quality of life is affected (GPP). 
The potential use of anti-muscarinics in a person 
with existing cognitive impairment should usually be 
discussed with a PD expert and the person / family 
should be made aware of the potential for cognitive 
worsening / hallucinations. 
Artificial nutrition and hydration 
Sometimes, a person with PD will develop a potential 
indication for artificial nutrition and / or hydration. If 
no preference has been expressed and the individual 
is not well enough to make a decision, the MDT must 
decide what is in their best interests, weighing up the 
advantages and disadvantages. Whilst artificial feeding 
(via gastrostomy, inserted either as a percutaneous 
endoscopic gastrostomy [PEG] or radiologically-inserted 
gastrostomy [RIG]), or hydration, can be beneficial in 
selected cases, where there is a reversible element to the 
person’s illness, it may not be appropriate, for example 
where the person has a limited life expectancy, poor 
quality of life or advanced dementia (please refer to later 
section on “Recognising advanced disease and limited 
life expectancy”). 
Therefore there are a number of key factors to be 
considered before either treatment is administered 
(EPDA64), including:
15
Palliative care in People with Parkinson’s disease
• respecting the individual’s wishes and 
acknowledging those of the carer and family
• allowing the individual, if competent, the right 
to decide whether they want to eat or not
• acting in the individual’s best interests
• maintaining wellbeing and the best possible 
quality of life
• providing supportive care
• minimising the effects of malnutrition
• minimising any side effects of treatment
When artificial feeding is an option, key factors that 
need to be taken into consideration include (EPDA65):
• hunger
• whether nutritional supplements are already 
being given
• if a desire to live or die has been expressed
• whether it is the individual’s wish that 
nutritional support be given
• whether such support might increase the risk 
of complications
Artificial hydration might improve some PD symptoms 
such as delirium, nausea, constipation and orthostatic 
hypotension but it might not alleviate symptoms such as 
a dry mouth or thirst, and in some cases it might worsen 
restlessness and incontinence. Of note, a Cochrane 
review in 200866 found that there were insufficient good 
quality studies to make any recommendations regarding 
the use of artificial hydration in palliative care patients 
(not specifically in PD).
Artificial nutrition and hydration at end of life: If a 
person already has a gastrostomy tube fitted, when 
dying it is often appropriate to reduce the volume of 
feed, or even to stop because of the body’s diminishing 
ability to handle fluid or nutrition. Continuing nutrition 
at this stage may even exacerbate some symptoms such 
as respiratory secretions.  A systematic literature review 
of artificial nutrition and hydration in the last week of 
life in cancer patients found little evidence that these 
improved symptoms or comfort67. Withdrawing feeding 
or fluids requires careful communication with family 
and carers, who may interpret these changes as a cause 
rather than a result of dying.  
Pressure ulceration
In the advanced stages of PD many people become 
immobile. This places individuals at risk of pressure ulcer 
development, and an assessment of risk for pressure 
ulcers should be a priority. Most pressure ulcers occur 
over a bony prominence. Dystonia and contractures of 
the limbs may cause pressure ulcers in more unlikely 
places. HCW should assist the carers in understanding 
how to move such physically dependent people and 
handle their relative safely. An occupational therapy 
assessment may assist in improving posture, and seating 
and sleeping positioning and cushioning (e.g. wheelchair 
review, pressure relieving cushions, gel heel / elbow / 
ear protectors). Skin pressure pain from immobility may 
be relieved by opioids. Pressure relieving devices for 
both the bed and chair should be used.
Proactive diagnosis particularly in the wheelchair bound 
patients is essential.  At every physician appointment, 
assessing skin integrity is important, especially 
examining the buttocks for those in wheelchairs, and 
lower back for those with malnutrition (GPP). 
Nausea
It is important to first consider any underlying causes 
(e.g. dehydration, constipation, infection, drug causes). 
Nausea due to dopaminergic medications may be 
lessened by taking the medications with food (although 
absorption may be affected). Many routine drugs 
used for nausea and vomiting, e.g. metoclopramide, 
cinnarizine, and prochlorperazine, have antagonistic 
effects on dopamine receptors. They have a very high 
risk of worsening Parkinson’s symptoms and should not 
be used. Antiemetics which are least likely to cause side-
effects in PD are (NCPC, 201210; EFNS late16)
• Domperidone, which can be used for gastric 
stasis type vomiting, can be given orally (oral 
suspension available), or via suppository. As 
it blocks peripheral dopamine conversion, it 
can help dopaminergic medication-related 
nausea (EFNS late). NB: domperidone has 
a HPRA warning of cardiac events (May 
2014) and so patients, if appropriate for their 
cognitive status, should be counselled about 
the risks and benefits of domperidone before 
treatment, and this conversation should be 







• Ondansetron may have a use for constant 
intractable nausea, but as a selective serotonin 
5HT-3 receptor antagonist, it is used mainly 
where there is disruption to the mucosa of the 
gut e.g. after chemotherapy or radiotherapy. 
It is recommended by the EFNS16 as a second 
line agent in PD and can be given by various 
routes. It can cause troublesome constipation.
• Cyclizine can also be considered. 
However cyclizine may worsen parkinsonism, 
and should be used with caution.
 
Fatigue and sleep disorders
Fatigue can occur at any stage of PD, and sleep 
disorders may affect up to 90% of people with PD68. 
Excessive somnolence can be particularly challenging 
for the individual and their families and carer. It can 
also represent a challenge to nursing staff concerning 
medication management, hydration, and nutrition.
NICE guidelines11 recommend that good sleep hygiene 
should be advised in people with PD with any sleep 
disturbance and includes: 
• avoidance of stimulants (for example, coffee, 
tea, caffeine) in the evening
• establishment of a regular pattern of sleep
• comfortable bedding and temperature
• provision of assistive devices, such as a bed 
lever or rails to aid with moving and turning, 
allowing the person to get more comfortable 
• restriction of daytime naps (e.g. suggestion 
that naps are short and earlier in the day)
• advice about taking regular and appropriate 
exercise to induce better sleep
Drug interventions can also be considered. First, all 
medication should be reviewed, specifically to avoid any 
drugs that may affect sleep or alertness, or may interact 
with other medication (e.g. selegiline, antihistamines, 
H2 antagonists, antipsychotics and sedatives). Input 
from pharmacy may be helpful if the person has multiple 
comorbidities to try to reduce overall medication burden 
and interactions.
For example, dopaminergic drugs can cause insomnia, as 
can selegiline, so night-time doses may need to be taken 
earlier. Conversely, if poor sleep is due to rigidity and 
inability to turn, dopaminergic medications, including 
controlled release preparations, may be helpful. Thus, 
a careful history of the pattern and causes of poor 
sleeping is vital. The person / carer should be questioned 
for restless leg symptoms, nocturia, obstructive sleep 
apnoea, Rapid Eye Movement sleep disorder, etc. 
Modafinil may be considered for daytime 
hypersomnolence in people with PD (EFNS late16, level 
B; NICE11, GPP; SIGN12 guidelines did not recommend 
Grade A). Two more recent small studies showed a 
trend towards, and a significant effect, respectively, in 
reducing excessive daytime sleepiness. A meta-analysis 
in 201369 (four studies, excluding the most recent 
positive study) found an overall benefit (overall Grade A 
evidence). Of note there has been no benefit shown in 
the symptom of fatigue. Thus, based on the most up to 
date evidence, we recommend a short trial of modafinil 
for hypersomnolence, with discontinuation if no effect. If 
not familiar with this medication, we recommend expert 
advice is sought.
Methylphenidate may also be considered in patients with 
fatigue (AAN15, Grade C).
Orthostatic hypotension
Orthostatic hypotension affects about 30-58% of people 
with PD70, particularly those with MSA, and can severely 
compromise quality of life. Notable causes include poor 
intake of fluids, side-effects of general medications such 
as anti-hypertensives, antidepressants, diuretics, other 
medical conditions such as cardiac dysfunction, and 
side-effects of all PD medications especially dopamine 
agonists.
General measures to combat orthostatic hypotension 
(adapted from EFNS16) should include: 
• Avoid aggravating factors such as large meals, 
alcohol, caffeine at night, exposure to a warm 
environment, volume depletion, and drugs 
known to cause orthostatic hypotension, such 
as diuretics or antihypertensive drugs, tricyclic 
antidepressants, nitrates, alpha-blockers 
used to treat urinary disturbances related to 
prostatic hypertrophy. Levodopa, dopamine 
agonists, and MAO-B inhibitors may also 
induce orthostatic hypotension. 
• Increase salt intake in symptomatic orthostatic 
hypotension.
• Head-up tilt of the bed at night (30 – 40°) may 
be helpful.
• Wear full leg length elastic stockings and 
abdominal binder if person can tolerate.
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• Exercise as tolerated.
• Introduce counter-manoeuvres to prolong 
the time for which the patient can be upright 
(leg crossing, toe raising, thigh contraction, 
bending at the waist).
• In some patients, hypotension occurs only 
postprandially so it is helpful to warn the 
patient about this.
Drug therapy can include midodrine (EFNS16, Gradel 
A); fludrocortisone (EFNS16, GPP, risk of side effects). 
However, there is limited evidence for these drugs. A 
PD expert should be consulted when considering such 
drugs.
Summary of physical care
PD causes many motor and non-motor symptoms 
throughout the disease, and the assessment and 
management of these can sometimes be difficult, 
particularly in advanced disease. If initial assessment 
and treatment attempts have not improved symptoms, 
it is important to re-assess the nature and cause of the 
symptom, and also to seek expert help. Clinicians with 
expertise in PD and SPC teams, often working together, 
can work with the primary physician and MDT to 
improve symptoms and comfort.   
Psychological 
Care
It is important to highlight that many psychological symptoms in PD 
may be a manifestation of an “off-state” (i.e. a period of low blood-brain 
dopamine levels, typically associated with rigidity and tremor as well 
as non-motor symptoms). For example, people may feel depressed or 
anxious transiently, improving with their next medications. This is different 
to pervasive symptoms that persist for days, weeks or months. Off-state 
symptoms should be aggressively targeted by PD medication review. 
Equally, visual hallucinations and delusions are often precipitated or 
worsened by PD medications, and again review of PD medications is a key 
component of their management.
Cognitive impairment and dementia
As the PD progresses, individuals will invariably 
experience increasing difficulty with working memory, 
problem-solving ability, and information processing 
speed. Dementia is a common feature of later disease, 
with prevalence of 24-31%71. Treatment options for 
dementia include the acetylcholinesterase inhibitors, 
rivastigmine (MDS14 conclusion efficacious; EFNS16 Late 
Grade A; AAN15 Grade B) and donepezil (EFNS16 Late 
Grade A ; AAN15 Grade B). Rivastigmine is available 
as a transdermal patch, which may be advantageous 
for compliance. Memantine can be considered for use 
if cholinesterases are not tolerated (e.g. worsening 
tremor), as there is some accruing evidence for its 
effectiveness (EFNS16 Grade C). Clinical (neuro)
psychology and / or  occupational therapy assessments 
can provide information on the nature and level of 
impairment present, and guide cognitive re-training and 
interventions to facilitate adaptation of daily routines, 
to maximise independence. Carer education is an 
important, allied role.
Visual hallucinations 
Visual hallucinations are common in people with PD, 
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and it is important to note that they may not need to 
be actively treated if they are well tolerated by the 
patient and carer (NICE11, GPP). Where the person is 
distressed, or there are other features of psychosis, 
consideration should be given to withdrawing gradually 
antiparkinsonian medication that might have triggered 
the psychosis in people with PD (NICE11, GPP). 
Medications should be withdrawn in the following order: 
Anticholinergics, amantadine, MAOB inhibitors, COMT 
inhibitors, dopamine agonists, and then finally, minimize 
levodopa (EFNS16, GPP). 
Typical antipsychotic drugs (such as phenothiazines and 
butyrophenones) should not generally be used in people 
with PD because they exacerbate the motor features of 
the condition (NICE11, GPP). Atypical antipsychotics may 
be considered for treatment of psychotic symptoms in 
people with PD, particularly quetiapine (AAN15, Grade C), 
although the evidence base for their efficacy and safety 
is limited. Patients with Lewy Body Dementia (LBD) 
will often present first with cognitive issues, and visual 
hallucinations / fluctuations in cognition are a hallmark 
of this disease. Particular care needs to be taken in 
using antipsychotics in patients with LBD as 50% show 
neuroleptic sensitivity reactions.
Clozapine at lower doses may be used in the treatment 
of psychotic symptoms in PD, but regular blood 
monitoring is required due to the propensity for 
causing agranulocytosis (NICE11, Grade B; MDS14, Grade 
A). Donepezil (EFNS16 late, Grade C) and rivastigmine 
(EFNS16 late, Grade B) may be beneficial for PD 
psychosis in the context of dementia.
NB sudden onset or worsening of hallucinations, 
especially accompanied by fluctuating cognition, 
attention and consciousness level, or deteriorated 
function, should raise the possibility of delirium (see later 
section).  
Depression
Up to 60 percent of people with PD experience mild or 
moderate depressive symptoms, both as a direct disease 
component and as a result of reduced function, loss of 
role, and reduced quality of life. It can be difficult to 
diagnose mild depression in people with PD as some 
symptoms of depression can simulate symptoms of 
Parkinson’s - such as feeling tired, lacking in energy and 
sleep and night-time problems. Clinicians should have a 
low threshold for diagnosing depression in PD (NICE11, 
Grade D). 
Mild depression may be helped by complementary 
therapies, and adjustments to routine such as getting 
good sleep, improved diet and better exercise; 
counselling may also be beneficial (GPP).
Moderate to severe depression in early / moderate 
severity PD may also be helped in the short-
term by cognitive behavioural therapy (Grade B). 
Antidepressants, mainly selective serotonin reuptake 
inhibitors (SSRIs), can be used to treat moderate 
or severe depression. SSRIs are considered to have 
“acceptable risk” for the treatment of depression 
in PD (MDS14) and are commonly used clinically. A 
recent trial72 comparing paroxetine, venlafaxine and 
placebo in patients with predominantly moderate PD 
(Hoehn and Yahr stages 2 and 2.5) found both active 
treatments superior to placebo (Grade B). Potential 
interactions with dopaminergic medications need to be 
considered. It is also useful to map depressive symptoms 
to medication timing and other “off” symptoms, as 
psychological symptoms including depression and 
anxiety are common during “off” periods. In this 
case, adjusting dopaminergic therapy may be helpful. 
Mirtazapine may worsen nightmares but its sedative 
effects at night are sometimes useful (GPP).
Pramipexole is a dopamine agonist which can be 
considered efficacious for the treatment of mild to 
moderate depression in PD (MDS14, Grade A). Of note, 
the most compelling study only included patients with 
mild-moderate PD (maximum Hoehn and Yahr stage 
3), and patients with motor fluctuations were generally 
excluded from the studies. 
Anxiety
Up to 40% of people with PD may experience anxiety, 
including generalised anxiety disorder or panic attacks, 
and anxiety symptoms are frequently comorbid with 
depression73. People with PD may worry about their 
symptoms worsening, and may worry about the future. 
Anxiety in PD can often be a wearing off symptom, and 
this should be assessed. SSRIs may be effective if anxiety 
is severe, although there are no randomised controlled 
trials in people with PD. Complementary therapies such 
as massage, yoga or gentle exercise may be beneficial 
(GPP). Counselling or cognitive behavioural therapy can 
also be effective in dealing with anxiety (GPP).
Drug therapy for anxiety also includes benzodiazepines 
(lorazepam, alprazolam, midazolam and diazepam). 
However, benzodiazepines may exacerbate falls and are 
pro-deliriogenic, so the risk / benefit must be carefully 
weighed up. 
Delirium
Delirium is an acute confusional state characterised 
by altered consciousness, and impaired attention 
and general cognitive function, which fluctuates in 
severity over minutes, hours or days74. Risk factors for 
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delirium include underlying cognitive impairment / 
dementia, older age, medical illness, hip fracture, and 
psychoactive medications75-77. Thus, people with PD are 
often particularly at risk of delirium when unwell, and 
HCW need to be particularly vigilant and not assume 
hallucinations or psychotic features are due to the PD 
syndrome. 
Delirium diagnosis may be particularly challenging in 
advanced PD, and requires assessment by a clinician 
with expertise in delirium diagnosis. However, when 
delirium is suspected, screening for reversible causes 
of delirium should be performed without delay, 
including ruling out urinary tract infections or retention, 
pneumonia, constipation, metabolic abnormalities, pain, 
medication toxicity, and, where indicated, intra-cranial 
events78.
There is no specific research into delirium 
treatment in advanced PD, but anti-psychotics and 
acetylcholinesterases are the usual treatment for 
delirium (NICE11 guidelines) and would be expected to 
also work in PD. As per the treatment of hallucinations 
discussed earlier, quetiapine is a mild antipsychotic 
which does not usually worsen PD motor symptoms 
(although it must be used with extreme caution in 
LBD). There is no research into the use of clozapine in 
delirium treatment. Although benzodiazepines have 
been historically used for the treatment of delirium and 
do not worsen motor symptoms, they do not treat the 
underlying psychotic thinking in delirium, and may in fact 
precipitate delirium79, so their use needs to be carefully 
considered and discussed with an appropriate expert. 
Agitation / delirium at end of life: Some degree of 
delirium has been reported in at least 80% of dying 
people and can give rise to restlessness or agitation. It 
is important to try to differentiate delirium from simple 
anxiety, although this can be particularly difficult at end 
of life in PD if the person’s communication ability and 
motor function is diminished. If delirium is likely, it is 
important to consider reversible causes, as appropriate 
for the setting and individual’s status (e.g. an enema 
for constipation may no longer be appropriate if death 
is anticipated within hours).  A quiet, non-stimulating 
environment and staff skilled in caring for a person at 
end of life are important components of care. If a person 
can swallow, consider quetiapine for delirium. Other 
antipsychotics are available for administration by other 
routes, but may worsen rigidity at a time where a person 
is often unable to swallow dopaminergic medications, 
and this must be carefully considered.
Benzodiazepines are frequently used at end of life for 
agitation/delirium, and they have anxiolytic properties. 
There are also theoretical benefits in PD due to their 
muscle relaxant properties, at a time where a person 
may not be able to take dopaminergic medications 
for rigidity9. There is some concern that they may 
paradoxically precipitate / worsen delirium79, although 
this has not been studied at end of life care or 
specifically in a PD population. Some degree of delirium 
has been reported in at least 88% of dying people and 
can give rise to restlessness or agitation.79a
A recent Cochrane review did not find sufficient 
evidence to support any palliative pharmacological 
sedation in terminally ill adults during their last few days 
of life80 (not specific to PD), but the guidelines group 
do note that pharmacological sedation is commonly 
used in clinical practice and is recommended in many 
general end of life care guidelines. The PD palliative 
care guidelines group recommends expert input, ideally 
from a team with joint PD / palliative care expertise, 
particularly if initial treatment attempts have not relieved 
the person’s distress. 
Terminal agitation / delirium can be very distressing to 
the person’s family. They should be supported by a team 
with skill in end of life care. Ongoing communication is 
important to help them understand the rationale for a 
decision to administer sedating medication, as well as 
the potential consequences.  
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• Fear of the disorder. It may be unknown to 
the person and their family, or there may be a 
family history of the disease, with memories of 
these experiences. Either may be a frightening 
prospect.
• Fear of the future, including fears around 
deterioration, dependency and dying.
• Fears for the family, including concerns about 
how their partner will cope with the death or 
being alone in bereavement.
• Fear of palliative care. Amongst the public 
(and HCW) there are common misperceptions 
about palliative care, firstly that it is applied 
only at the end of life; and second, that it is 
synonymous with late-stage cancer care. A 
reminder of the focus on the quality of life of 
the person with PD and an explanation of the 
model of dynamic involvement of palliative 
care throughout the illness would be helpful 
as would referring the person with PD and 
family carers to the resources to the AIIHPC’s 
Palliative Hub (see Appendix VII for list of 
relevant websites).  
• Losses of independence and ability to 
undertake day-to-day activities as a parent, 
spouse, sexual partner or participant in sport 
or other leisure activity.
• Fears of losing abilities, mobility, personal care, 
feeding, toileting, sexual function.
• Practical issues of finances, housing, making a 
will and ensuring care for dependants.
• Cognitive changes: as the person loses 
cognitive ability they may initially be aware 
of this and fear the progression and loss of 
awareness and brain function.
• Multiple losses for both the person and their 
family involving many of the items listed 
above. This, and the changing family roles 
involved, may be profound.
Advice and support may be necessary, from counselling 
and social work support in coping with fears and 
losses through to financial planning and social 
services provision. Referral to occupational therapy 
and physiotherapy may be beneficial to promote 
independence, mobility, and continued participation in 
activities. Meaningful occupation is very important for 
people who are losing their life roles and may help to 
maintain their sense of personhood. Referral to clinical 
(neuro)psychology services can be helpful in cases 
of difficult or complex adaptation to the challenges 
linked to disease progression. Integrating systemic, 
psychological and neuropsychological data may 
allow the MDT to understand and mitigate barriers to 
engaging with patients whose care has been challenging 
to date. 
HCW can refer carers to PD advocacy groups including 
the PAI, Move4Parkinson’s, Progressive Supranuclear 
Palsy Association Limited (PSPA Ireland), the Multiple 
System Atrophy Trust. Individual support may also 
be required. The websites for these organisations are 
included in the list of relevant websites in Appendix VII.
Social Care
As someone faces the diagnosis and then the progression of a life-limiting 
condition such as PD there will be many psychosocial issues that come to 
the fore, including (adapted from NHS England9):
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It is important that all HCW should be able to offer 
spiritual care that reaches out to an individual in their 
time of need. A key aspect of spiritual care involves 
listening to individual narratives to learn their ‘life-
story’. An understanding of what was important to 
the individual before cognitive decline may help. 
However, many HCW will not feel equipped to fully 
explore and address spiritual care needs with their 
patients. Therefore, referral to SPC and / or chaplaincy 
services is important where there are unmet spiritual 
needs. Contact with an appropriate supportive network 
may also help the family. In Ireland, specialist care 
may be provided by personnel from various religious 
denominations, or by lay chaplains, who encompass 
the beliefs and views of all denominations. Also refer 
to the Health Services Executive (HSE) Health Services 
Intercultural Guide82.
People who have religious beliefs are often greatly 
helped by religious support during their illness. Religious 
beliefs may also become more important to the relatives 
as death becomes inevitable. Cultural and religious 
differences around the end of life deserve respect. It 
is important to recognise the increasing diversity of 
religious beliefs in Ireland, and to facilitate people of all 
religions, and those with no organised religion. 
Aids to prayer can be helpful when words are not 
possible, e.g. rosary beads, prayer tablet, or candles. The 
same applies to physical contact other than just within 
care tasks, such as hand holding or a gentle massage. 
This may not be appropriate / acceptable for everyone 
depending on cultural beliefs.
Where appropriate, the individual and family should 
be asked about care of the person’s body after death, 
including religious practices9.
Spiritual Care
Palliative care takes a holistic view of the patient and family. This includes 
addressing the spiritual care needs of person with PD. The exact definition 
of spiritual care is not widely agreed. One definition of spirituality is ‘a 
personal search for meaning and purpose in life’81. It is clear however that 
spirituality is not synonymous with religion, and that the assessment of 
spiritual needs is much more than a tick-box question about religious 
affiliation. Similarly, spiritual care needs will change as PD progresses, and 
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Recognising advanced disease and limited life 
expectancy
Identifying when someone with PD may be approaching 
their last months of life is very important, e.g. for 
advance care planning. However, this can be particularly 
difficult in PD where the disease trajectory typically 
follows a long progressive decline over many years. 
Indicators that could suggest that life expectancy is now 
very limited are often either not recognised or ignored. 
There is a need for greater openness and discussion of 
dying and death to address this issue.
Below are some specific indicators that have been 
suggested to identify that the person with PD has a 
limited life expectancy (i.e. less than six months; Gold 
Standards Framework). However, regular assessments 
are vital to identify the various triggers that may suggest 
there is a relevant deterioration in a person’s condition. 
Please refer also to the National Clinical Programme for 




In some cases symptoms may be reversible, for example 
where there is an inter-current infection, and it is 
important to identify and treat any such problems.
Gold Standards Framework - Clinical prognostic 
indicator83: 
Two or more of: 
• Drug treatment not effective or complex 
regime needed
• More unpredictability of control
• Reduced independence
• Dyskinesias / mobility problems / falls
• Swallowing difficulties
• Psychiatric symptoms
Recognising end of life or “actively dying phase”
It is similarly important to recognise when death is 
imminent. This allows a change in the focus of care, 
and gives family members some warning of the 
approaching death. Recognising imminent death can 
be particularly challenging in PD where a person has 
slowly deteriorated over a prolonged period of time. The 
experience of the guidelines advisory group is also that 
the dying phase of PD can be unpredictable, sometimes 
occurring over days or weeks, rather than hour or days. 
Planning Future 
Care and End of 
life Care in PD
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Staff caring for the person and family members should 
be advised of this, to avoid carer exhaustion.    
 
Withdrawing / rationalising treatment
Idiopathic PD. In the later stages of PD there may 
be the need to review, and reduce or withdraw, 
dopaminergic drugs due to lack of drug efficacy and 
increasing sensitivity to unwanted effects such as visual 
hallucinations and excessive somnolence. The person 
with PD and their carers at this stage will sometimes 
want to reduce medications, exchanging greater levels 
of physical disability for increased mental clarity (NICE11 
guideline). However some psychological symptoms (e.g. 
“off” related anxiety) could be made worse, so constant 
review is required. As a general guide, medication 
withdrawal should be managed with help from the 
specialist clinician and Parkinson’s disease Nurse 
Specialist. Where possible, drug withdrawal should be 
gradual in order to achieve the best balance between 
relief of symptoms and minimal side effects. 
This situation should however be reviewed on an 
ongoing basis as frequent adjustments may be required 
to maintain this balance.
In people who have undergone deep brain stimulation 
(DBS) surgery for PD, it is recommended that the 
DBS is only switched off at end of life if it is causing 
complications for the person, as switching it off may 
precipitate rigidity / dystonia / pain. 
Parkinsonian Syndromes. People with MSA and 
PSP are less responsive to dopamine replacement 
therapy, and the benefits of continued use need to be 
particularly considered in these people as the disease 
progresses. Timely and regular review and management 
of the increasing symptom load, addressing physical, 
psychological, social, and spiritual aspects, is vital to 
improving quality of life. 
Preferred place of death 
Part of care planning for people in their home (whether 
in the community or residential care) is to establish their 
preferred place of death, bearing in mind that people’s 
wishes may change over time. One important focus of 
care at end of life is to avoid an inappropriate hospital 
admission. However, there is no one setting of care that 
is “better” than others as a place of death and the critical 
factor is that the setting can meet the complexity of the 
person’s care needs at end of life. Appropriate reliable 
support must be readily accessible to professional and 
non-professional carers at all times, including weekends 
and out-of-hours.
Support for professionals
Caring for a person with PD can be challenging at times 
and at its core it requires MDT input, with knowledge 
sharing in a timely fashion. Staff also need the basic 
resources to provide the level of care that they feel the 
person needs; otherwise their role can be stressful, when 
they identify a care need but can’t address it. 
End of life care can also be difficult for the staff member. 
It is important that staff support themselves and each 
other in this area of work. Staff can be supported 
through peer support, informal debriefing sessions or 
counselling as appropriate84.
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While it is important to recognise the relationship of 
the patient and carer, equally the carer must also be 
recognised as an individual.
People caring for someone with PD may face many 
challenges. They may feel like they have already ‘lost 
the person’ and experience episodes of grieving. Family 
may not see the end coming. Carers may be separated 
from their loved one if they transition to residential care. 
Carers who experience a high care burden for a long time 
may experience feelings of emptiness and guilt when the 
person with PD enters residential care or dies. 
Carers often have their own support needs. Everyday 
contact with the outside world might be limited, 
compounding isolation. Carers should be directed to 
agencies which can provide invaluable support, such as:
• Family Carers Ireland
• The AIIHPC Palliative Hub 
• the Parkinson’s Association of Ireland 
• PSPA Ireland (Supports people with PSP and 
CBD)
• Multiple System Atrophy Trust
• Move4Parkinson’s 
Carers should also be offered individual support, as in 
some cases group support can actually increase carer 
anxiety (for example if they see people with more 
advanced disease than their loved one).
Particular challenges to carers of people with PD are the 
cognitive, personality, and behavioural changes that may 
occur, especially in advanced stages of disease. These 
changes are associated with much greater carer burden. 
Referral to a psychologist may help carers understand 
and cope.
The Parkinson’s Association of Ireland has branches 
across Ireland which offer support groups to people with 
PD and their carers. Further information can be found at: 
http://www.parkinsons.ie/branches 
Bereavement care. Bereavement care is appropriate 
throughout the disease process, not just at end of life. 
However, it comes into focus in the end of life phase, 
during death, and following the relative’s death. People 
with neurological disease and carers are often very 
frightened of the dying process, and may be more fearful 
of the process than of the death itself. 
If they ask what to expect near the end of life, 
appropriate information on further support is essential as 
well as opportunities to share their concerns and fears. 
Some individuals and their carers will have been told that 
their condition is not one people die from and therefore 
may be unprepared, especially for severe progression 
and rapid death.
Sometimes families need help to recognise the signs that 
death is approaching. Equally, carers could be the first 
to recognise and interpret subtle changes in reduced 
energy, engagement and mood as the neurological 
condition worsens. Carers should be kept informed about 
significant changes in care management, for example in 
oral feeding and hydration. 
If there are unmet social, psychological, physical, or 
spiritual needs, swift referral to SPC and / or chaplaincy 
services may be required. This is important to prevent 
severe distress amongst carers.
Bereaved families may benefit from three levels of 
support (www.bereaved.ie86): 1. General support and 
information (e.g. information on the grieving process, 
help with practical tasks, social support), 2. Extra support 
(e.g. voluntary bereavement support services, faith 
groups, community groups), 3. Therapy support (e.g. 
psychologists, counsellors, doctors).
Carers
An estimated 12,000 people in Ireland are diagnosed with PD19, and 
therefore carers of people with PD represent a sizeable portion of the 
187,112 people who were identified as carers in the 2011 census85.
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HCW should be able to advise individuals on the 
following, and refer on to other supports where 
appropriate. It is most important that the person with 
PD has the opportunity to complete any necessary 
legal documents while they still have the capacity to do 
this (with a decision making assistant or a co-decision 
maker, as needed), and so HCW must be proactive in 
discussing future planning with the patient early in the 
disease course. Physicians caring for people with PD and 
related syndromes should be trained and competent 
in assessing decision making capacity, and all HCW 
should be familiar with assisted decision making as per 
the Assisted Decision Making (Capacity) Act 201587. The 
detailed legislation surrounding assisted decision making 
is outside the scope of these guidelines. 
Wills. Everyone aged 18 or over can - and should 
- make a will to ensure that when they die their 
property, including a house or flat, money and personal 
belongings, is distributed exactly as they would 
wish. Most solicitors in general practice can draw up a 
simple will. If a will was written long ago, it should be 
reviewed and updated if necessary. 
Enduring power of attorney. If a person anticipates that 
they will become unable to manage his or her legal and 
financial affairs, he or she may need to appoint someone 
he or she trusts to act on his or her behalf, such as a 
relative, friend or solicitor. This legal document can 
allow another person to make financial and personal 
care decisions (e.g. where you live) for someone who 
has lost the ability to make his or her own decisions. 
The person who makes an enduring power order can 
change or revoke it at any time while he or she retains 
mental capacity; the enduring power of attorney is only 
registered (comes into force) when the person has lost 
their decision making capacity.
Advance care directives. Sometimes called “living 
wills”, these allow the person to give instructions about 
medical treatments that he/she does or doesn’t want if 
he/she becomes terminally ill and is unable to express 
his/her wishes. The Assisted Decision-Making (Capacity) 
Act 201587  contains the current legislation on advance 
care directives, and HCWs caring for a person with PD 
should become familiar with these. It is anticipated that 
there will be a specific code of practice developed to 
guide HCWs in this area.   
 It is important to note that a person has the right to 
refuse a particular treatment, but does not have the right 
to demand specific treatment. For the most updated 
position, please refer to: http://www.citizensinformation.
ie/en/health/legal_matters_and_health/advance_care_
directives.html.
Brain bank and research
Researchers, including those who are working towards 
a cure for Parkinson’s disease, are collecting tissue from 
people with PD following their death. Some people may 
find it comforting to know that they can contribute to 
this cause following their death, but this needs to be a 
very sensitive discussion. Further information about the 
Dublin Brain Bank can be found at http://www.rcsi.ie/
index.jsp?a=960&n=797&p=331 
Legal issues
There are a number of legal issues which an individual with PD and their 
families need to address before the end of life phase and before cognitive 
decline. Often just knowing that the future has been thought about and 
planned for can bring a sense of calm and relief for everyone involved, 
making it easier for all to cope. HCW may need to actively prompt a 
patient to begin discussions about legal and financial affairs. 
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AAN American Academy of Neurology
ACP Advance Care Plan
AIIHPC All Ireland Institute of Hospice and Palliative Care
CBD Corticobasal Degeneration
ECG Electrocardiogram 
EDPA European Parkinson’s disease Association
EFNS European Federation of Neurological Societies (EFNS)
FDA U.S Food and Drug Administration 
GPP Good Practice Point
HCW Healthcare worker
HSE Health Service Executive
IHF Irish Hospice Foundation
LBD Lewy body dementia
MAO-B Monoamine oxidase B
MDT Multidisciplinary Team
MSA Multiple System Atrophy
NA Neurological Alliance (UK)
NACPC National Advisory Committee on Palliative Care
NCEC National Clinical Effectiveness Committee 
NCPC The National Council for Palliative Care (UK) 
NELC National End of Life Care Programme (UK)
NG tube Nasogastric tube
NHS National Health Service
NICE National Institute for Health and Care Excellence
PAI Parkinson’s Association of Ireland
PD Parkinson’s disease
PDD Parkinson’s disease Dementia
PDNS Parkinson’s disease Nurse Specialist
PEG Percutaneous Endoscopic Gastrostomy
PRN “pro re nata” i.e. Latin phrase meaning ‘use as necessary’.
PSP Progressive Supranuclear Palsy
PSPA Progressive Supranuclear Palsy Association
REM Rapid eye movement
SIGN Scottish Intercollegiate Guidelines Network
SPC Specialist Palliative Care
SSRI Selective Serotonin Reuptake Inhibitor
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NICE – Classification of recommendations and evidence statements
Grade Evidence Type of Evidence
A • At least one meta-analysis, 
systematic review, or
randomised controlled trial 
(RCT) that is rated as 1++,
and is directly applicable to the 
target population, or
• A systematic review of RCTs 
or a body of evidence that
consists principally of studies 
rated as 1+, is directly
applicable to the target 
population and demonstrates
overall consistency of results, or
• Evidence drawn from a NICE 
technology appraisal 
1++ High-quality meta-analysis 
(MA), systematic
reviews (SR) of randomized 
controlled trials
(RCTs), or 
RCTs with a very low risk of bias
1+ Well-conducted MA, SR or 
RCTs, or RCTs
with a low risk of bias
B • A body of evidence that 
includes studies rated as 2++, is
directly applicable to the target 
population and
demonstrates overall 
consistency of results, or
• Extrapolated evidence from 
studies rated as 1++ or 1+
2++ High-quality SR of case-
control or cohort studies
2++ High-quality case-control or 
cohort studies with a
very low risk of confounding, 
bias or chance and a
high probability that the 
relationship is causal
2+ Well-conducted case-control 
or cohort studies with a
low risk of confounding, bias or 
chance and a
moderate probability that the 
relationship is causal
C • A body of evidence that 
includes studies rated as 2+, is
directly applicable to the target 
population and
demonstrates overall 
consistency of results, or
• Extrapolated evidence from 
studies rated as 2++
D • Evidence level 3 or 4, or
• Extrapolated evidence from 
studies rated as 2+, or
• Formal consensus
3 Non-analytic studies (for 
example case reports, case
series)
4 Expert opinion, formal 
consensus
D(GPP) A good practice point (GPP) is a 
recommendation for
best practice based on the 
experience of the Guideline
Development Group
Grading criteria used by existing guidelines
Appendix III
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SIGN - Classification of recommendations and evidence statements
LEVELS OF EVIDENCE
1++ High quality meta-analyses, systematic 
reviews of RCTs, or RCTs with a very low 
risk of bias
1+ Well conducted meta-analyses, systematic 
reviews, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews, or RCTs 
with a high risk of bias
2++ High quality systematic reviews of case 
control or cohort studies
2+ Well conducted case control or cohort 
studies with a low risk of confounding or 
bias and a moderate probability that the
relationship is causal
2- Case control or cohort studies with a high 
risk of confounding or bias and a significant 
risk that the relationship is not
Causal




A At least one meta-analysis, systematic 
review, or RCT rated as 1++,
and directly applicable to the target 
population; or
A body of evidence consisting principally of 
studies rated as 1+,
directly applicable to the target population, 
and demonstrating overall consistency of 
results
B A  body of evidence including studies rated 
as 2++,
directly applicable to the target population, 
and demonstrating overall consistency of 
results; or
Extrapolated evidence from studies rated as 
1++ or 1+
C A body of evidence including studies rated 
as 2+,
directly applicable to the target population 
and demonstrating overall consistency of 
results; or
Extrapolated evidence from studies rated as 
2++
D Evidence level 3 or 4; or





Recommended best practice based on 








A • Established as effective, ineffective, or harmful for the given condition in the 
specified population.
• Level A rating requires at least two consistent Class I studies
B • Probably effective, ineffective, or harmful for the given condition in the 
specified population.
• Level B rating requires at least one Class I study or at least two consistent Class 
II studies.
C • Possibly effective, ineffective, or harmful for the given condition in the 
specified population.
• Level C rating requires at least one Class II study or two consistent Class III 
studies.
U • Data inadequate or conflicting given current knowledge, treatment is unproven
Movement Disorder Society – Classification of Evidence
Efficacy conclusions Definition Required evidence
Efficacious Evidence shows that 
intervention has a positive 
effect on studied outcomes
Supported by data from at least 
1 high-quality (score ≥ 75%)
RCT without conflicting level-I 
data
Likely efficacious Evidence suggests, but is not 
sufficient to show, that
the intervention has a positive 
effect on studied outcomes
Supported by data from any 
Level-I trial without conflicting
level-I data
Unlikely efficacious Evidence suggests that the 
intervention does not have
a positive effect on studied 
outcomes
Supported by data from any 
Level-I trial without conflicting
level-I data
Non-efficacious Evidence shows that the 
intervention does not have a
positive side effect on studied 
outcomes
Supported by data from at least 
1 high-quality (score ≥ 75%)
RCT without conflicting level-I 
data.
Insufficient evidence There is not enough evidence 
either for or against efficacy of 
the intervention in treatment of 
Parkinson’s disease
All the circumstances not 
covered by the previous 
statements
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European Federation of Neurological Societies - Classification of Evidence
Recommendation grade Evidence
A established as effective, ineffective, or harmful, 
requires at least one convincing class I study or 
at least two consistent, convincing class II studies
B probably effective, ineffective, or harmful, 
requires at least one convincing class II study or 
overwhelming class III evidence
C possibly effective, ineffective, or harmful rating, 
requires at least two convincing class III studies
GPP where there is insufficient scientific evidence, a 
consensus statement (“good practice point”)
Simplified grading scheme used in the Canadian guidelines
Recommendation grade Evidence
A Established as effective, ineffective, or harmful for the given condition in 
the specified population.
B Probably effective, ineffective, or harmful for the
given condition in the specified population.
C Possibly effective, ineffective, or harmful for the
given condition in the specified population.
D Expert opinion, formal consensus.
U Data inadequate or conflicting given current
knowledge, treatment is unproven.
GPP Good practice point.
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As part of the systematic review, four databases were searched in February and March 2015. The databases 
searched were: Emabase, Medline, Cinanhl, and PsychInfo. The review included articles published since January 2010. 
The search terms used, limiters applied, and number of ‘hits’ are reported in the tables below.
MEDLINE (via Ovid) searched on 27/02/15
Search terms Hits
1 exp Parkinson disease/ 48907
2 parkinson disease.mp. 54162
3 Parkinson*.mp. 83216
4 exp Supranuclear palsy, progressive/ 1922
5 exp Lewy Body Disease/ 2204
6 exp Multiple System Atrophy/ 2714
7 exp Basal Ganglia Diseacorttheses/ 86771
8 exp Parkinsonian Disorders/ 59637
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 110466
10 exp Therapeutics/ 3416475
11 exp Pharmaceutical Preparations/ 620047
12 Palliative Care/ 41286





18 exp Qualitative Research/ 22139
19 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 6463589
20 exp Muscle Rigidity/ 1789
21 exp Pain/ 314310
22 Dysphagia.mp. or exp Deglutition Disorders/ 49293
23 exp Dyspnea/ 15978
24 exp Nausea/ 16021
25 Pressure Sores.mp. or exp Pressure Ulcer/ 10384
26 exp Fatigue/ 21107
27 exp Sleep Disorders/ 63521
28 exp “Disorders of Excessive Somnolence”/ 5575
29 exp Hypotension, Orthostatic/ 4941
30 exp Memory/ or exp Memory Disorders/ 116962
31 exp Cognition/ 112909
32 exp Hallucinations/ 9173
33 exp Depression/ 79319
34 exp Anxiety/ 57586
35 exp Delirium/ 6027
36 exp Accidental Falls/ 16113
37 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 
35 or 36
812549
38 9 and 19 and 37 4201
39 limit 37 to humans; yr=”2010 -Current” 1128
Appendix IV
Search strategy used for systematic review
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Cinahl (via Ebsco) searched on 12/03/15
Search terms Hits
S1 (MM “Parkinson Disease”) OR (MM “Lewy Body Disease”) OR (MM 
“Supranuclear Palsy, Progressive”) OR “multiple system atrophy” OR (MM 
“Parkinsonian Disorders”) OR “corticobasal degeneration”
11,356
S2 “treatment” OR (MM “Treatment Outcomes+”) OR (MM “Drugs+”) OR (MM 
“Palliative Care”) OR (MM “Terminal Care+”) OR (MH “Intervention Trials”) 
OR (MM “Nursing Interventions”) OR (MM “Crisis Intervention”) OR (MM 
“Experimental Studies+”) OR (MM “Evaluation”) OR (MM “Drug Evaluation+”) 
OR (MM “Program Evaluation”) OR (MM “Evaluation Research”) OR (MM 
“Quality of Life+”) OR (MM “Health and Life Quality (Iowa NOC) (Non-
Cinahl)”) OR (MM “Qualitative Studies+”)
617,783
S3 (MM “Pain+”) OR “rigidity” OR (MM “Swallowing Therapy”) OR “dysphagia” 
OR (MM “Dyspnea+”) OR (MM “Nausea”) OR (MM “Nausea Care (Saba 
CCC)”) OR (MM “Nausea and Vomiting+”) OR (MM “Pressure Ulcer+”) 
OR (MH “Fatigue”) OR (MH “Sleep Disorders”) OR (MM “Hypotension, 
Orthostatic+”) OR (MM “Memory Disorders+”) OR (MM “Cognition 
Disorders+”) OR (MM “Depression+”) OR (MM “Anxiety+”) OR (MM 
“Hallucinations+”) OR (MM “Delirium”) OR (MM “Accidental Falls”) 
201,226
S4 S1 AND S2 AND S3 372
S5 S1 AND S2 AND S3
Limit: humans
Limit Jan 2010 to Mar 2015
115
PsychInfo (via Ebsco) searched on 12/03/15
Search terms Hits
S1 SU ( ‘Parkinson* disease’ OR ‘Parkinsonian’ OR ‘Parkinson*’ ) OR SU 
‘progressive supranuclear palsy’ OR SU ( ‘lewy body dementia’ OR ‘Lewy 
Body disease ) OR SU ‘multiple system atrophy’ OR SU ‘parkinson disease 
dementia’ OR SU ‘corticobasal degeneration’ 
19,069
S2 SU therapy OR SU drug* OR SU intervention OR SU evaluation study OR SU 
(‘qualitative study’ OR ‘qualitative research’) OR SU pharmatherapy OR SU 
pharmacological OR SU ( ‘palliative therapy OR ‘palliative care’ )
477,552
S3 SU ‘muscle rigidity’ OR SU pain OR SU ( ‘dysphagia’ OR ‘swallow difficulty’ 
) OR SU ( dyspnea OR ‘breathing difficulty’ OR ‘shortness of breath’ ) OR 
SU nausea OR SU ( ‘decubitus’ OR ‘pressure sore’ OR ‘pressure ulcer’ ) OR 
SU fatigue OR SU ‘sleep disorder’ OR SU ( ‘orthostatic hypotension’ OR 
‘postural hypotension’ ) OR SU ( ‘memory disorder’ OR ‘cognition’ ) OR SU 
( ‘depression’ OR ‘delirium’ OR ‘anxiety’ ) OR SU ‘visual hallucination’ OR SU 
(falls OR fall OR balance) 
297,295
S4 S1 AND S2 AND S3 611
S5 S1 AND S2 AND S3
Limiters - Publication Year: 2010-2015; Published Date: 20100101-20150331; 
Population Group: Human
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Embase (via Elsevier) searched on 13/03/15  
1 ‘parkinson disease’/exp OR ‘parkinson disease’  101,782
2 ‘parkinsonian’ 13,096
3 ‘progressive supranuclear  palsy’/exp OR ‘progressive supranuclear palsy’ 4,942
4 ‘diffuse lewy body disease’/exp OR ‘diffuse lewy body disease’ 4,574
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5 ‘multiple system atrophy’/exp OR ‘multiple system atrophy’ OR ‘shy drager 
syndrome’/exp OR ‘shy drager syndrome’ 
5,036
6 ‘parkinson disease dementia’ 144
7 ‘corticobasal degeneration’/exp OR ‘corticobasal degeneration’ 2,198
8 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 113,272
9 ‘therapy’/exp OR ‘therapy’ 8,948,294
10 ‘intervention studies’/exp OR ‘intervention studies’ 29,439
11 ‘drug mechanism’/exp OR ‘drug mechanism’ 275,004
12 palliative AND (‘therapy’/exp OR therapy) 96,122
13 ‘evaluation research’/exp OR ‘evaluation research’ OR ‘evaluation study’/exp 
OR ‘evaluation study’
194,283
14 ‘qualitative analysis’/exp OR ‘qualitative analysis’ OR ‘qualitative research’/exp OR 
‘qualitative research’
75,013
15 9 OR 10 OR 11 OR 12 OR 13 OR 14 9,233,762
16 ‘muscle rigidity’/exp OR ‘muscle rigidity’ 8,850
17 ‘pain’/exp OR ‘pain’ 1,095,915
18 ‘dysphagia’/exp OR ‘dysphagia’ 51,627
19 ‘dyspnea’/exp OR ‘dyspnea’ 108,523
20 ‘nausea’/exp OR ‘nausea’ 197,539
21 ‘decubitus’/exp OR ‘decubitus’ 18,766
22 ‘fatigue’/exp OR fatigue 167,846
23 ‘sleep disorder’/exp OR ‘sleep disorder’ 169,471
24 ‘orthostatic hypotension’/exp OR ‘orthostatic hypotension’ 17,887
25 ‘memory disorder’/exp OR ‘memory disorder’ 54,425
26 ‘cognition disorder’/exp OR ‘cognition disorder’ OR ‘cognitive defect’/exp 
OR ‘cognitive defect’
103,578
27 ‘visual hallucination’/exp OR ‘visual hallucination’ 4,948
28 ‘depression’/exp OR ‘depression’ 494,142
29 ‘anxiety’/exp OR ‘anxiety’ 236,805
30 ‘falling’/exp OR ‘falling’ OR ‘falls’ 92,104
31 ‘delirium’/exp OR ‘delirium’ 21,691
33 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 
OR 29 OR 30 OR 31
2,183,256
34 8 AND 15 AND 33 19,145
#34 AND [humans]/lim AND [2010-2015]/py 7,600  
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A total of 21 submissions were received.  Personal 
submissions included submissions from allied health 
professionals, family carers of people with a Parkinsonian 
syndrome, and others who expressed a personal interest 
in the area. The organisations which had members 
provide feedback are listed below. Note that the 
guidelines were also distributed to organisations in 
addition to those listed below, however only those listed 
provided feedback.
Two international experts on palliative care for people 
with neurodegenerative diseases were invited to provide 
feedback as part of this process, prior to the wider 
public consultation. These experts were Professor David 
Oliver, Consultant in Palliative Medicine, Rochester, and 
Honorary Reader, the University of Kent; and Professor 
Anette Schrag, Professor of Clinical Neurosciences, 
University College London.
• All Ireland Gerontological Nurses Association 
(AIGNA)
• Association of Occupational Therapists  of 
Ireland (AOTI) - Palliative Care and Oncology 
Advisory  Group  
• Health Service Executive Quality Improvement 
Division
• Irish Association of Speech and Language 
Therapists (IASLT)
• Irish College of General Practitioners (ICGP) - 
Quality in Practice Committee 
• Irish Institute of Clinical Neuroscience (IICN)
• Irish Society of Chartered Physiotherapists 
(ISCP) - Chartered Physiotherapists in 
Neurology and Gerontology Clinical Interest 
Group 
• Irish Society of Physicians in Geriatric Medicine 
(ISPGM) 
• Multiple System Atrophy Trust
• National Clinical Programmes for Neurology, 
Palliative Care, and Older Persons
• The National Social Work Organisation of 
Ireland - Head Medical Social Workers Group 
and the Social Workers in Aging Special 
Interest Group
• Nursing Homes Ireland (NHI)




At the time of diagnosis the professionals involved 
in the care of the person with PD may be the GP, 
consultant neurologist / geriatrician with a speciality in 
Parkinson’s disease, or Clinical Nurse Specialist in PD. 
However throughout the disease an increasing number 




• Neuro / Clinical psychologists
• Occupational therapists





• Public health nurses
• Rehabilitation physicians
• Social services managers
• Social workers
• Specialist palliative care
• Speech and language therapists
• Voluntary organisations, e.g. the Parkinson’s 
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The website of the Parkinson’s Association of Ireland 
(PAI) the national support and advocacy charity for 
Parkinson’s in Ireland. Information for professional 
healthcare workers is available on the website, including 
the following link: 
http://www.parkinsons.ie/professionals_palliativecare
The Multiple System Atrophy Trust is a UK based charity 
supporting people affected by multiple system atrophy. 
They also have information about support for healthcare 
professionals at the following link:
http://www.msatrust.org.uk 
PSPA Ireland is a voluntary organisation which supports 
people who have or are affected by Progressive 
Supranuclear Palsy or Corticobasal Degeneration. 
Information on both PSP and CBD is available through 
their website:
www.pspaireland.ie 
The Irish Hospice Foundation (IHF) is a national charity 
dedicated to all matters relating to dying, death and 
bereavement in Ireland. The IHF website provides a 
wealth of information, including that specific to the care 





The website ‘Bereaved.ie’ has links to a range of 
supports and training for people who work (in a 




Further information about the Dublin Brain Bank tissue 
donation can be found at: http://www.rcsi.ie/index.
jsp?a=960&n=797&p=331
The websites for the Health Service Executive National 
Clinical Programmes contain useful information, 
including downloadable documents and links to other 
websites/resources.
The National Clinical Progamme for Palliative care 
website is available at:
http://www.hse.ie/eng/about/Who/clinical/natclinprog/
palliativecareprogramme/ 




The National Clinical Progamme for Older People 
website is available at: 
http://www.hse.ie/eng/about/Who/clinical/natclinprog/
olderpeopleprogramme/ 
All Ireland Institute of Hospice and Palliative Care 
(AIIHPC), with the palliative care sector, have developed 
‘The Palliative Hub’ to act as a gateway to information 
and resources about palliative care on the island of 
Ireland. There are sub-sections of the Hub aimed at 
different groups, as follows:
The Palliative Hub – Adult is aimed at adults with 
palliative care needs, their family members and carer’s, 
including the wider public engaged with someone with a 
palliative need:
http://aiihpc.org/palliative-hub/adult-public/
The Palliative Hub – Learning Platform provides an 
online learning environment for both professionals and 
the public to learn about palliative care and build upon 
their current knowledge:
http://aiihpc.org/palliative-hub/learning-platform/
The  Palliative Hub – Professional is currently in 
development (launching Spring 2016) and will be aimed 
at health and social care professionals, academics, 
researchers, educationalists and volunteers working in 
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